Navigation Links
Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
Date:5/6/2010

VIENNA, May 6 /PRNewswire-FirstCall/ -- Intercell AG (VSE: ICLL) today announced that it has signed an agreement with Cytos Biotechnology Ltd. to acquire Cytos' platform technology for monoclonal antibody discovery. The technology is based on expression cloning of monoclonal antibodies from human B-cells and enables the identification of anti-infective antibodies to prevent and treat infectious diseases.

Under the agreed terms Intercell will pay EUR 15 million to Cytos. Intercell will own certain unpartnered monoclonal antibody assets, including promising pre-clinical anti-infective antibody candidates discovered by Cytos. The key scientists, who have very successfully developed the technology at Cytos, will be employed by Intercell. The antibody technology complements Intercell's technology platforms and opens novel medically and commercially relevant applications for Intercell's Antigen Identification Program (AIP®). The AIP® has delivered promising vaccine candidates against Staphylococcus aureus (Phase II/III) and Pneumococcus (Phase I) infections, among others, and has also been the basis for partnerships in the antibody field with Merck & Co. and Kyowa Hakko Kirin in these indications, respectively.

In its future antibody discovery activities Intercell will focus on medically and commercially attractive AIP® derived disease targets including Group B Streptococcus and bacteria involved in hospital acquired infections.

"Cytos' outstanding antibody technology complements our innovative R&D technology platform and enables pipeline progression within our existing portfolio," stated Gerd Zettlmeissl, Chief Executive Officer of Intercell.

Wolfgang Renner, CEO of Cytos, commented
'/>"/>

SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
2. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
3. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
4. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
5. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
6. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
7. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
8. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
9. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
10. U.S. Preventive Medicine Acquires Specialty Disease Management
11. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... YORK and LONDON , ... of market intelligence, MarketResearch.com is pleased to announce the ... and Consultancy focusing on the active pharmaceutical ingredient (API) ... visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . In IQ4I,s ... – Forecast to 2020 , IQ4I ...
(Date:11/26/2014)... YORK , Nov. 25, 2014  Medtronic,s ... Covidien has been widely discussed in the ... it,s also creating a stronger leading player in ... to Kalorama Information.  The healthcare market research firm ... systems will feature a diverse set of solutions ...
(Date:11/26/2014)... 2014  Breckenridge Pharmaceutical, Inc. announced today that ... with Pii (Pharmaceutics International, Inc.) ( Hunt ... Pii expect to develop and commercialize several new ... will develop, manufacture and supply the products, and ... its own label.  The drugs, comprised of four ...
Breaking Medicine Technology:MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2
... , WILMINGTON, Del., Oct. 16 AstraZeneca ... and Drug Administration (FDA) approved CRESTOR® (rosuvastatin calcium) ... familial hypercholesterolemia (HeFH) when diet therapy fails to reduce ... characterized by high LDL cholesterol (the "bad" cholesterol) and ...
... CITY, Oct. 15 Dynatronics Corporation (Nasdaq: DYNT ) ... a letter from Nasdaq stating that the Company has not ... from Nasdaq. , Nasdaq provides the Company an opportunity to ... panel is authorized to grant up to 180 additional calendar ...
Cached Medicine Technology:U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 2U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 3U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 4
(Date:11/26/2014)... The family foundation of Best Buy founder, ... Research Foundation (Meso Foundation), half of which will be ... Grant Program . The focus area of the Richard ... with organizations that can generate transformational results in education, ... founder and chairman emeritus of Best Buy Co., Inc., ...
(Date:11/26/2014)... German scientists say carbon-based synthetic molecules used in ... looks and acts similar to asbestos-induced mesothelioma. Surviving Mesothelioma ... Click here to read it now. , ... Medicine in Hannover injected 500 lab rats with multi-walled ... developed mesothelioma , how quickly it developed appeared ...
(Date:11/26/2014)... Los Angeles, CA (PRWEB) November 26, 2014 ... Los Angeles orthopedic surgeon Dr. Steven Meier has ... site to offer current and prospective patients an online ... , “We’re really excited to present the new and ... and added features make it easier than ever for ...
(Date:11/26/2014)... 2014 ISI Telemanagement Solutions, Inc., ... been award the 2014 Lync Pioneer Award ... comes as a great honor to ISI, who ... ecosystem. Specifically, ISI offers an integrated collaboration reporting ... communication, including voice, video, Lync IM, and conferencing. ...
(Date:11/26/2014)... 26, 2014 For those with a New ... LES MILLS BODYPUMP™ classes at the University of Colorado ... they've been looking for. The 45- 60 minute classes have ... and Wellness Center fitness club memberships. , LES MILLS BODYPUMP™ ... fast-paced and are aimed at fast results , By ...
Breaking Medicine News(10 mins):Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 2Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2
... found that primitive immune systems of fruit flies may ... that immune memory was not possible for insects. ... Medicine could have implications for new ways of developing ... ,The evidence that a fruit fly's immune ...
... Human embryonic stem cells (hESCs) hold great promise for ... provide evidence// that stem cell-derived nerve cells may integrate ... ,This study was conducted by an international collaboration led ... a member of his lab, Jean-Pyo Lee, Ph.D., of ...
... TVs contain possibly hazardous chemicals called polybrominated diphenyl ethers ... of Standards and Technology and the Environmental Protection Agency ... not yet clear how dangerous these PBDEs are, though ... Their structure is strikingly similar to that of PCBs, ...
... risk of prostate cancer amongst Japanese men by as much ... ,"To our knowledge, this is the first prospective study to ... in Japanese, whose intake of soy food is high," wrote ... ,Over half a million news cases of prostate cancer ...
... team of scientists who have achieved a major breakthrough in ... cancer// tumors in humans. ,Anindya Bagchi, along with ... (CSHL), a private research institute in Long Island, New York, ... cells to misbehave and tumors to form. ,The ...
... Unprocessed cocoa is reported to have huge health benefits ... anesthesia//. This was disclosed by Norman Hollenberg, professor of ... suggests that Epicatechin which is found in high levels ... four major and common diseases of the western world ...
Cached Medicine News:Health News:Flies too Have Immune Memory! 2Health News:Flies too Have Immune Memory! 3Health News:Stem Cells Hold Promise for Treating Neurodegenerative Diseases 2Health News:Stem Cells Hold Promise for Treating Neurodegenerative Diseases 3Health News:Stem Cells Hold Promise for Treating Neurodegenerative Diseases 4Health News:Stem Cells Hold Promise for Treating Neurodegenerative Diseases 5Health News:Soy Isoflavones Linked to Lower Prostate Cancer Risk 2
Nitinol Tipless Stone Basket...
1.5 Fr Nitinol Tipless Stone Basket...
Rapid latex agglutination test for presumptive identification of E. coli serogroup O157:H7 isolates. Colorimetric with red O157 latex and blue H7 latex....
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG...
Medicine Products: